Ranjana Advani

Ranjana Advani

UNVERIFIED PROFILE

Are you Ranjana Advani?   Register this Author

Register author
Ranjana Advani

Ranjana Advani

Publications by authors named "Ranjana Advani"

Are you Ranjana Advani?   Register this Author

100Publications

4645Reads

37Profile Views

Reply to J. Wang et al.

J Clin Oncol 2019 Mar 12;37(9):755-757. Epub 2019 Feb 12.

David M. Kurtz, MD, PhD; Florian Scherer, MD; Michael C. Jin; Joanne Soo; Alexander F.M. Craig, MPhil; Mohammad S. Esfahani, PhD; Jacob J. Chabon, PhD; Henning Stehr, PhD; Chih Long Liu, PhD; Robert Tibshirani, PhD; Lauren S. Maeda, MD; Neel K. Gupta, MD; Michael S. Khodadoust, MD, PhD; Ranjana H. Advani, MD; and Aaron M. Newman, PhD, Stanford University, Stanford, CA; Ulrich Dührsen, MD; and Andreas Hüttmann, MD, University Hospital Essen, Essen, Germany; Michel Meignan, MD, PhD, Hôpitaux Universitaires Henri Mondor, Creteil, France; Olivier Casasnovas, MD, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski, MD; and Wyndham H. Wilson, MD, PhD, National Institutes of Health, Bethesda, MD; Gianluca Gaidano, MD, PhD; and Davide Rossi, MD, PhD, University of Eastern Piedmont, Novara, Italy, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; and Maximilian Diehn, MD, PhD; and Ash A. Alizadeh, MD, PhD, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01907
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01907DOI Listing
March 2019

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Br J Haematol 2019 01 28;184(1):17-29. Epub 2018 Nov 28.

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15616DOI Listing
January 2019

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.

N Engl J Med 2019 01;380(5):497-498

Forty Seven, Menlo Park, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816156DOI Listing
January 2019

Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy.

Radiother Oncol 2018 12 6;129(3):507-512. Epub 2018 Jul 6.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2018.06.033DOI Listing
December 2018

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

N Engl J Med 2018 Nov;379(18):1711-1721

From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1807315DOI Listing
November 2018

Risk-adapted therapy for advanced-stage Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):200-206

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245987PMC
November 2018

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2018 10 20;36(28):2845-2853. Epub 2018 Aug 20.

David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Maximilian Diehn, and Ash A. Alizadeh, Stanford University, Stanford, CA; Florian Scherer, University Medical Center Freiburg, Freiburg; Ulrich Dührsen and Andreas Hüttmann, University Hospital Essen, Essen, Germany; Michel Meignan, Hôpitaux Universitaires Henri Mondor, Creteil; René-Olivier Casasnovas, Hôpital Le Bocage, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski and Wyndham H. Wilson, National Cancer Institute, National Institutes of Health, Bethesda, MD; Gianluca Gaidano and Davide Rossi, University of Eastern Piedmont, Novara, Italy; and Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.5246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161832PMC
October 2018

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

J Clin Oncol 2018 10 4;36(30):3015-3022. Epub 2018 Sep 4.

Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ranjana H. Advani, Stanford University, Stanford, CA; Irene B. Helenowski, Borko D. Jovanovic, Jane N. Winter, and Leo I. Gordon, Northwestern University Feinberg School of Medicine; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center; Sonali M. Smith, University of Chicago, Chicago, IL; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Gregory R. Bociek, University of Nebraska, Omaha, NE; Andreas K. Klein, Tufts Medical Center, Boston, MA; and Paul A. Hamlin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0139DOI Listing
October 2018

Novel Approaches in Waldenström Macroglobulinemia.

Hematol Oncol Clin North Am 2018 Oct 19;32(5):875-890. Epub 2018 Jul 19.

Division of Oncology, Department of Medicine, Stanford University, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183074
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.05.014DOI Listing
October 2018

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Blood Adv 2018 07;2(13):1547-1550

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018021071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039652PMC
July 2018

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

Am Soc Clin Oncol Educ Book 2018 May;38:626-636

From the Department of Medicine, Division of Oncology, Stanford University, Stanford, CA; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; Perlmutter Cancer Center at NYU Langone Health, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200679DOI Listing
May 2018

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

Br J Haematol 2018 01 18;180(1):164-166. Epub 2016 Aug 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14302DOI Listing
January 2018

Advances in the management of primary mediastinal large B-cell lymphoma.

Authors:
Ranjana H Advani

Clin Adv Hematol Oncol 2018 Jan;16(1):33-34

Stanford Cancer Institute, Stanford, California.

View Article

Download full-text PDF

Source
January 2018

Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Curr Treat Options Oncol 2017 10;18(10):60

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-017-0499-4
Publisher Site
http://dx.doi.org/10.1007/s11864-017-0499-4DOI Listing
October 2017

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88 Mutation.

Case Rep Oncol 2017 Sep-Dec;10(3):813-818. Epub 2017 Sep 12.

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/480292
Publisher Site
http://dx.doi.org/10.1159/000480292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649220PMC
September 2017

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Br J Haematol 2017 07 25;178(1):72-80. Epub 2017 May 25.

Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487277PMC
July 2017

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Curr Treat Options Oncol 2017 07;18(7):45

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0483-zDOI Listing
July 2017

The landscape of new drugs in lymphoma.

Nat Rev Clin Oncol 2017 Jun 29;14(6):335-346. Epub 2016 Dec 29.

UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611863PMC
June 2017

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.

Am Soc Clin Oncol Educ Book 2016 ;35:e376-85

From the Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159036DOI Listing
January 2017

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.

Leuk Lymphoma 2016 28;57(3):604-8. Epub 2015 Aug 28.

a Department of Radiation Oncology , Stanford University School of Medicine , Stanford , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1067700DOI Listing
December 2016

Speeding up PET/MR for cancer staging of children and young adults.

Eur Radiol 2016 Dec 5;26(12):4239-4248. Epub 2016 Apr 5.

Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052123PMC
http://dx.doi.org/10.1007/s00330-016-4332-4DOI Listing
December 2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Am J Clin Oncol 2016 12;39(6):535-544

*University of Rochester Medical Center, Rochester †††Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, New York, NY †Stanford Cancer Center, American Society of Clinical Oncology, Stanford ‡University of Southern California Keck School of Medicine, Los Angeles, CA §University of Texas MD Anderson Cancer Center, Houston ¶University of Texas Health Science Center at San Antonio, San Antonio, TX ∥Emory University, American Society of Clinical Oncology, Atlanta, GA #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††St. Jude Children's Research Hospital, American Society of Clinical Oncology, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶The University of Chicago, American Society of Hematology, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000331DOI Listing
December 2016

2 Gy × 2 for palliative treatment of mantle cell lymphoma.

Leuk Lymphoma 2016 09 14;57(9):2219-21. Epub 2016 Jan 14.

a Department of Radiation Oncology , Stanford Cancer Institute, Stanford University , Stanford , CA , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1131274DOI Listing
September 2016

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J Natl Compr Canc Netw 2016 09;14(9):1067-79

From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0117DOI Listing
September 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.

Am J Clin Oncol 2016 08;39(4):384-95

*Yale University School of Medicine, New Haven, CT †Memorial Sloan Kettering Cancer Center, New York, American Society of Clinical Oncology ¶University of Rochester Medical Center, Rochester, NY ‡Princess Margaret Hospital, Toronto, ON, Canada §Stanford Cancer Center, Stanford, CA, American Society of Clinical Oncology ∥University of Texas MD Anderson Cancer Center, Houston **University of Texas Health Science Center at San Antonio, San Antonio, TX #Emory University, Atlanta, GA, American Society of Clinical Oncology ††University of Florida Proton Therapy Institute, Jacksonville ‡‡University of Florida, Gainesville, FL §§St Jude Children's Research Hospital, Memphis, TN, American Society of Clinical Oncology ∥∥University of Pennsylvania Health System, Philadelphia, PA ¶¶Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ##The University of Chicago, Chicago, IL, American Society of Hematology ***Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD †††Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000294DOI Listing
August 2016

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Ther Adv Hematol 2016 Aug 13;7(4):179-86. Epub 2016 Jun 13.

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620716654102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959643PMC
August 2016

Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

Radiology 2016 07 8;280(1):220-9. Epub 2016 Feb 8.

From the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, and Department of Medical Oncology (R.A.), Stanford University Medical Center, 300 Pasteur Dr, Stanford, CA 94305-5281 (R.M., A.Q.); Department of Radiology, Molecular Imaging Program, Stanford University, Stanford, Calif (R.M.); Departments of Lymphoma/Myeloma (L.F.) and Nuclear Medicine (H.M.), the University of Texas, MD Anderson Cancer Center, Houston, Tex; Oncology/Hematology Section (J.V.) and Department of Radiology (J.H.), University of Nebraska Medical Center, Omaha, Neb; Department of Biostatistics, University of Nebraska Medical Center College of Public Health, Omaha, Neb (J.M.); Department of Nuclear Medicine, University Hospital of Aachen, Aachen, Germany (F.M.); and Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan (M.J.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2015150689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934532PMC
July 2016

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.

Clin Adv Hematol Oncol 2016 Jul;14(7):543-54

Stanford University Medical Center, Stanford, California.

View Article

Download full-text PDF

Source
July 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Arch Pathol Lab Med 2016 Apr 15. Epub 2016 Apr 15.

From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Duncavage and Rosenbaum); the Departments of Medicine, Oncology Division (Dr Advani), and Pathology (Dr Ohgami), Stanford University Medical Center, Stanford, California; the Pathology & Laboratory Medicine Service, James A. Haley Veterans Affairs Medical Center, Tampa, Florida (Drs Agosti, Foulis, and Kang); the Moffitt Cancer Center, Tampa, Florida (Ms Gibson); the Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston (Drs Khoury, Medeiros, and Patel); the Department of Pathology, Clarient Pathology Services, Aliso Viejo, California (Dr O'Malley); and the Department of Hematopathology, University of New Mexico Health Sciences Center, Albuquerque (Dr Wilson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2015-0418-CPDOI Listing
April 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Arch Pathol Lab Med 2016 Apr 15. Epub 2016 Apr 15.

From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Duncavage and Rosenbaum); the Departments of Medicine, Oncology Division (Dr Advani), and Pathology (Dr Ohgami), Stanford University Medical Center, Stanford, California; the Pathology & Laboratory Medicine Service, James A. Haley Veterans Affairs Medical Center, Tampa, Florida (Drs Agosti, Foulis, and Kang); Blood and Marrow Transplantation, the Moffitt Cancer Center, Tampa, Florida (Ms Gibson); the Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston (Drs Khoury, Medeiros, and Patel); the Department of Pathology, Clarient Pathology Services, Aliso Viejo, California (Dr O'Malley); and the Department of Hematopathology, University of New Mexico Health Sciences Center, Albuquerque (Dr Wilson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2016-0045-CPDOI Listing
April 2016

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.

Am J Clin Oncol 2015 Dec;38(6):610-20

*University of Texas MD Anderson Cancer Center, Houston, TX †American Society of Clinical Oncology, Stanford Cancer Center, Stanford, CA ‡Princess Margaret Hospital, Toronto, Ontario, Canada §University of Rochester Medical Center ‡‡‡University of Rochester Medical Center, Rochester †††American Society of Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ∥American Society of Clinical Oncology, Emory University, Atlanta, GA ¶Univeristy of Texas Health Science Center at San Antonio, San Antonio, TX #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††American Society of Clinical Oncology, St. Jude Children's Research Hospital, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶American Society of Hematology, University of Chicago, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/COC.0000000000000215DOI Listing
December 2015

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

J Clin Oncol 2015 Nov 20;33(32):3750-8. Epub 2015 Jul 20.

Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie Nguyen-Lin, Wen-Kai Weng, Randall Armstrong, and Ranjana H. Advani, Stanford University, Stanford, CA; Katrin A. Salva and Gary S. Wood, University of Wisconsin and William S. Middleton Memorial Veterans Hospital, Madison, WI; and Melissa Pulitzer and Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089160PMC
November 2015

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.

Curr Treat Options Oncol 2015 Sep;16(9):45

Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0360-6DOI Listing
September 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.

Hematol Oncol 2015 Jun;33 Suppl 1:90-5

Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2226DOI Listing
June 2015

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

Int J Radiat Oncol Biol Phys 2015 May;92(1):67-75

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.02.001DOI Listing
May 2015

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

Int J Radiat Oncol Biol Phys 2015 May;92(1):99-106

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.039DOI Listing
May 2015

Ibrutinib in previously treated Waldenström's macroglobulinemia.

N Engl J Med 2015 Apr;372(15):1430-40

From the Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute (S.P.T., C.K.T., K.M., D.W., G.Y., Y.C., L.X., C.J.P., S.K., I.G., J.J.C., J.P.L., Z.R.H.), Harvard Medical School (S.P.T., G.Y., Y.C., S.R., J.C.A., N.L.H., I.G., J.J.C., J.P.L.), Department of Pathology, Brigham and Women's Hospital (S.R., J.C.A.), Department of Pathology, Massachusetts General Hospital (N.L.H.), and Department of Pathology, Boston University Medical Center (Z.R.H.) - all in Boston; Memorial Sloan Kettering Cancer Center, New York (R.G., K.V.A., M.L.P.); and Stanford University Medical Center, Stanford (G.V., J.L.Z., R.H.A.), and Pharmacyclics, Sunnyvale (Z.S., J.L., M.C., F.C., T.G.) - both in California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1501548DOI Listing
April 2015

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

J Clin Oncol 2015 Mar 20;33(7):740-8. Epub 2015 Jan 20.

Lynne I. Wagner and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Fengmin Zhao, Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Michael E. Williams, University of Virginia, Charlottesville, VA; John C. Krauss, University of Michigan, Ann Arbor, MI; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Ronald S. Go, Gunderson Health System, La Crosse; Brad S. Kahl, University of Wisconsin, Madison, WI; Thomas M. Habermann, Mayo Clinic, Rochester; Joseph W. Leach, Metro Minnesota Community Clinical Oncology Program, Minneapolis, MN; Brian O'Connor, Frederick Memorial Health System, Frederick, MD; Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; and Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/7/740.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6801
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334777PMC
March 2015